Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
Recent Advances in Hematology and Oncology
share announcement

Recent Advances in Hematology and Oncology

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Clinical Laboratory Medicine".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 874

Special Issue Editor

Dr. Chohao Lee

E-Mail Website
Guest Editor
1. Department of Internal Medicine, School of Medicine, National Defense Medical Center, Taipei City, Taiwan
2. Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, Taipei City, Taiwan
Interests: hematology; oncology; evidence-based medicine

Special Issue Information

Dear Colleagues, 

Greetings! 

This Special Issue is dedicated to showcasing recent breakthroughs in the fields of hematology and oncology, providing a comprehensive overview of cutting-edge research that contributes to our understanding of oncological and hematological malignancies. 

We welcome submissions of articles that explore emerging therapies, diagnostic techniques, and molecular insights, offering valuable perspectives for researchers, clinicians, and healthcare practitioners alike. Key themes to be addressed include precision medicine, immunotherapy, genomics, and targeted therapies. Through this initiative, our goal is to serve as an indispensable resource, bridging knowledge gaps and fostering further advancements in the dynamic realms of hematology and oncology. 

We eagerly anticipate your contributions to this Special Issue, and we believe that your insights will significantly contribute to the collective knowledge in these crucial fields. 

Dr. Chohao Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hematological malignancies
  • lymphoma
  • leukemia
  • multiple myeloma
  • precision medicine
  • immunotherapy
  • genomics
  • targeted therapies

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

6 pages, 4724 KiB  
Interesting Images
Nodal Low-Grade B-Cell Lymphoma Co-Expressing CD5 and CD10 but Not CD23, IRTA1, or Cyclin D1: The Diagnostic Challenge of a Splenic Marginal Zone Lymphoma
by Khin-Than Win, Yen-Chuan Hsieh, Hung-Chang Wu and Shih-Sung Chuang
Diagnostics 2024, 14(6), 640; https://doi.org/10.3390/diagnostics14060640 - 18 Mar 2024
Viewed by 681
Abstract
The diagnosis of lymphoma is based on histopathological and immunophenotypical features. CD5 and CD10 are traditionally considered a T-cell antigen and a germinal center B-cell antigen, respectively. It is very unusual for a low-grade B-cell lymphoma (BCL) to co-express CD5 and CD10. Although [...] Read more.
The diagnosis of lymphoma is based on histopathological and immunophenotypical features. CD5 and CD10 are traditionally considered a T-cell antigen and a germinal center B-cell antigen, respectively. It is very unusual for a low-grade B-cell lymphoma (BCL) to co-express CD5 and CD10. Although the biologic basis or clinical significance of such co-expression is unclear, this rare event may pose a significant diagnostic challenge. Here, we report a case of a 63-year-old male presenting with bilateral cervical lymphadenopathy and lymphocytosis. Histologically, the nodal tumor was largely diffuse with neoplastic small atypical lymphocytes co-expressing CD5, CD10, and CD20, but not CD23 or cyclin D1. The leukemic cells in the peripheral blood exhibited hairy projections. Taking together the marked splenomegaly, involvement of lymph nodes, bone marrow, and peripheral blood, a final diagnosis of splenic marginal zone lymphoma (SMZL) was reached. The patient was alive with partial response for 10 months after immunochemotherapy. The dual expression of CD5 and CD10 is extremely unusual for low-grade BCL and may lead to an erroneous diagnosis. Integrating the findings into peripheral blood smear tests, flow cytometry, histopathology, imaging, and clinical features is mandatory to exclude other lymphoma types and to reach a correct diagnosis, particularly for a case with nodal presentation. Full article
(This article belongs to the Special Issue Recent Advances in Hematology and Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop